Breckenridge Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRECKENRIDGE, and what generic and branded alternatives to BRECKENRIDGE drugs are available?
BRECKENRIDGE has forty-four approved drugs.
There are three tentative approvals on BRECKENRIDGE drugs.
Summary for Breckenridge
US Patents: | 0 |
Tradenames: | 43 |
Ingredients: | 43 |
NDAs: | 44 |
PTAB Cases with Breckenridge as petitioner: | See PTAB cases with Breckenridge as petitioner |
Drugs and US Patents for Breckenridge
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breckenridge | MIGLUSTAT | miglustat | CAPSULE;ORAL | 209325-001 | Feb 3, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Breckenridge | LAMIVUDINE | lamivudine | TABLET;ORAL | 203586-001 | Nov 21, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Breckenridge | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 207503-001 | Apr 30, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for BRECKENRIDGE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Here is a list of applicants with similar names.